Hydroxyamphetamine

Hydroxyamphetamine: Overview

Hydroxyamphetamine is an organic phenethylamine derivative and indirect-acting sympathomimetic amine. Chemically, it belongs to the class of organic compounds known as amphetamines and derivatives within the phenethylamines sub-class of benzenoids. Structurally, it consists of a 1-phenylpropan-2-amine (amphetamine) skeleton bearing a hydroxyl group (-OH) at the para-position (C4) of the benzene ring, possessing a molecular weight of 151.21 g/mol.

What Is Hydroxyamphetamine and How Does It Work?

Hydroxyamphetamine acts primarily through presynaptic uptake into postganglionic sympathetic nerve terminals to displace and release stored norepinephrine, which stimulates post-junctional alpha-1 adrenergic receptors on the iris dilator muscle, driving pupillary dilation (mydriasis) without cycloplegia and allowing pharmacological localization of Horner’s syndrome lesions.

Is Hydroxyamphetamine FDA Approved?

Hydroxyamphetamine hydrobromide 1.0% ophthalmic solution (co-formulated with tropicamide 0.25%) was approved by the US FDA on January 30, 1992, under the trade name Paremyd. Its current regulatory status is FDA Approved.

What Was/Is Hydroxyamphetamine Used For?

• Induction of rapid diagnostic mydriasis (pupillary dilation) for ophthalmoscopy, fundus photography, and retinal examinations.
• Differential neuro-pharmacological localization of lesions in Horner’s syndrome (distinguishing third-order postganglionic lesions from first- or second-order preganglionic lesions).
• Diagnostic mydriasis in pediatric and adult patients requiring rapid pupillary dilation with minimal disruption of near accommodation.

Before Taking Hydroxyamphetamine: Contraindications & Precautions

Do not administer Hydroxyamphetamine to patients with a known severe hypersensitivity to hydroxyamphetamine, amphetamine derivatives, tropicamide, or formulation excipients (including benzalkonium chloride). It is strictly contraindicated in patients with untreated narrow-angle glaucoma or anatomically narrow anterior chamber angles, as mydriasis can displace the peripheral iris against the trabecular meshwork, precipitating an acute angle-closure glaucoma crisis.

Who Should Not Take Hydroxyamphetamine?

• Individuals with narrow-angle glaucoma or anatomically narrow anterior chamber angles.
• Patients with known severe hypersensitivity or allergy to Hydroxyamphetamine or amphetamine derivatives.
• Patients taking systemic monoamine oxidase inhibitors (MAOIs).

Hydroxyamphetamine, Pregnancy & Safety

Systemic exposure following single-drop topical ophthalmic instillation is low. However, sympathomimetic amines can induce uterine vascular constriction. Animal reproduction studies evaluating Hydroxyamphetamine have not been formally conducted. It is classified as Pregnancy Category C.

Tell Your Doctor Before Taking Hydroxyamphetamine

Inform your ophthalmologist, optometrist, or physician if you have a history of narrow-angle glaucoma, high intraocular pressure, severe heart disease, high blood pressure, hyperthyroidism, or psychiatric disorders, or if you are taking monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants.

Hydroxyamphetamine Dosage & Administration

Formulated as a sterile, topical ophthalmic solution (1.0% w/v [10 mg/mL] hydroxyamphetamine hydrobromide co-formulated with 0.25% w/v tropicamide).

Hydroxyamphetamine dosing is limited to single-dose diagnostic applications.

Standard Hydroxyamphetamine Dosing

• Diagnostic Mydriasis Dosing (Adults & Children): Instill 1 drop of 1.0% Hydroxyamphetamine solution into the conjunctival sac of the eye(s) 15 to 30 minutes prior to diagnostic fundus examination.
• Horner’s Syndrome Differential Diagnosis Dosing: Instill 1 drop of 1.0% Hydroxyamphetamine solution into both eyes simultaneously; evaluate pupillary diameter after 45 to 60 minutes in ambient room lighting.

• Normal / Preganglionic Lesion (1st/2nd Order): Affected pupil dilates equally to or greater than the normal pupil.
• Postganglionic Lesion (3rd Order): Affected pupil fails to dilate (or dilates significantly less than the normal eye).

How Was/Is Hydroxyamphetamine Administered

• Tilt head back, pull lower eyelid down to form a pouch, hold dropper bottle vertically, and instill 1 drop into the conjunctival sac without touching the eye or eyelid.
• Perform Nasolacrimal Occlusion: Press finger firmly against the inner corner of the eye (lacrimal sac) for 1 to 2 minutes post-instillation to block systemic drainage down the nasolacrimal duct.
• Remove contact lenses prior to instillation; wait at least 15 minutes before reinserting soft contact lenses.

Hydroxyamphetamine Clinical Efficacy & Research

In clinical neuro-ophthalmology, diagnostic optometry, and ocular pharmacology research, Hydroxyamphetamine is established as a gold-standard diagnostic agent. Clinical trials evaluating Hydroxyamphetamine 1.0% co-formulated with tropicamide 0.25% (Paremyd) demonstrate that a single drop produces rapid, robust mydriasis (> 6.0 mm pupillary diameter) within 15 to 20 minutes, achieving maximal dilation at 30 to 45 minutes and recovering normal pupillary reflexes within 3 to 6 hours. Clinical comparative studies establish that combining indirect-acting Hydroxyamphetamine with low-dose direct-acting tropicamide achieves equivalent or superior pupillary dilation to 2.5% phenylephrine or 1.0% tropicamide monotherapy, but with significantly lower recovery times and minimal loss of near-focus accommodation.

Hydroxyamphetamine Side Effects & Safety Profile

Hydroxyamphetamine exhibits a favorable safety profile when administered as a single diagnostic dose. Safety hazards stem primarily from transient visual impairment and rare systemic sympathomimetic effects.

Adverse effects are localized predominantly to the ocular surface and visual function.

Common Hydroxyamphetamine Side Effects

• Ophthalmic Application: Transient ocular stinging, burning upon instillation, photophobia (increased sensitivity to bright light), blurred near vision, and temporary loss of color contrast perception.
• General: Dry mouth, mild headache, and temporary difficulty with night driving.

Serious Hydroxyamphetamine Adverse Events

• Acute Angle-Closure Glaucoma: Pupillary dilation triggering mechanical angle closure in eyes with shallow anterior chambers, causing severe eye pain, halos, nausea, and rapid intraocular pressure elevation.
• Systemic Sympathomimetic Toxicity: Tachycardia, systemic hypertension, cardiac arrhythmias, palpitations, and severe headache secondary to systemic absorption.
• Serotonergic / Monoamine Interactions: Central nervous system excitation or hypertensive crisis if administered to patients taking active MAOIs.

Managing Hydroxyamphetamine Side Effects

Advise patients to wear dark sunglasses following diagnostic examinations to alleviate photophobia. Instruct patients not to drive at night until mydriasis resolves. If acute eye pain or severe headache develops post-instillation, evaluate intraocular pressure immediately for angle closure.

Hydroxyamphetamine Drug Interactions & What to Avoid

Hydroxyamphetamine displays important pharmacodynamic interactions with monoamine oxidase inhibitors, tricyclic antidepressants, and guanethidine.

Co-administration with specific drug classes alters presynaptic norepinephrine kinetics or systemic blood pressure.

Hydroxyamphetamine Drug-Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs – Phenelzine, Selegiline): MAOIs inhibit norepinephrine degradation; presynaptic release of norepinephrine by Hydroxyamphetamine can precipitate a severe, acute hypertensive crisis; avoid concurrent use.
• Tricyclic Antidepressants (Desipramine, Imipramine) & Cocaine: Block the neuronal norepinephrine transporter (NET); inhibition of NET blocks presynaptic import of Hydroxyamphetamine, abolishing its mydriatic effect and producing a false-positive Horner’s test.
• Guanethidine & Reserpine: Deplete presynaptic norepinephrine stores in postganglionic sympathetic terminals; long-term therapy abolishes Hydroxyamphetamine-induced mydriasis.
• Systemic alpha-1 Blockers (Prazosin, Tamsulosin): Directly block post-junctional alpha-1 adrenergic receptors on the iris dilator, blunting mydriasis.

Hydroxyamphetamine, Food & Alcohol

Systemic food interactions do not occur with single-dose topical ophthalmic administration. Alcohol consumption does not directly alter topical ophthalmic hydroxyamphetamine pharmacokinetics.

Hydroxyamphetamine: Missed Dose, Overdose & Storage

Proper handling of Hydroxyamphetamine involves single-dose diagnostic instillation in clinical settings. Overdose is rare with topical application.

Adherence to proper storage parameters prevents chemical oxidation of the phenethylamine structure.

Missed Dose of Hydroxyamphetamine

Not applicable. Hydroxyamphetamine is administered as a single diagnostic dose by a eye care professional during a clinical examination.

Hydroxyamphetamine Overdose & Emergency

Topical ocular overdose is self-limiting as excess liquid drains from the conjunctival sac. Accidental oral ingestion of an entire 15 mL bottle of 1.0% solution yields 150 mg of hydroxyamphetamine hydrobromide, which can cause central nervous system stimulation, severe hypertension, tachycardia, hyperthermia, and cardiac arrhythmias. Emergency management includes immediate gastric lavage or activated charcoal, IV fluid resuscitation, administration of short-acting alpha-adrenergic antagonists (phentolamine) or short-acting beta-blockers for severe hypertension/tachycardia, and intensive supportive care.

How to Store Hydroxyamphetamine

Store Hydroxyamphetamine 1.0% ophthalmic solution at controlled room temperature between 15°C and 25°C (59°F to 77°F). Protect strictly from freezing and direct light exposure. Keep bottle tightly closed when not in use. Keep out of reach of children.

Hydroxyamphetamine Patient Management & Monitoring

Clinical oversight for patients receiving Hydroxyamphetamine focuses on evaluating baseline anterior chamber angle depth, monitoring post-instillation pupillary response, and assessing cardiovascular stability.

Regular clinical tracking ensures successful diagnostic mydriasis without ocular or systemic complications.

Tests Before Starting Hydroxyamphetamine

Baseline anterior chamber angle evaluation (van Herick slit-lamp assessment or gonioscopy) to rule out narrow angles; baseline intraocular pressure (IOP) check; baseline blood pressure and heart rate measurement in high-risk cardiovascular patients; evaluation for current medications blocking NET transporters.

Monitoring During Hydroxyamphetamine Treatment

Inspecting pupillary diameter at 15, 30, and 60 minutes post-instillation; evaluating pupillary symmetry in Horner’s syndrome testing; assessing patient comfort and photophobia post-examination.

Hydroxyamphetamine Do’s and Don’ts

• Do press the inner corner of your eye for 1 to 2 minutes after receiving drops to minimize systemic drug absorption.
• Do wear dark sunglasses after your eye exam to protect your eyes from bright sunlight.
• Do inform your eye doctor if you take antidepressants, blood pressure pills, or MAO inhibitors.
• Do not drive at night or operate machinery until your pupils return to normal size and blurred vision resolves.
• Do not receive Hydroxyamphetamine drops if you have untreated narrow-angle glaucoma.
• Do not rub your eyes after receiving diagnostic drops.

Frequently Asked Questions

References

• DrugBank Database – Hydroxyamphetamine Clinical Profile (DB09352)
• Classyfire Database – Amphetamines and Derivatives / Phenethylamines Taxonomy Profile
• Surveys of Ophthalmology – Neuro-Ophthalmic Pharmacological Testing in Horner’s Syndrome

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.